Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Gynaecological cancer

Novel molecular subtypes of cervical cancer — potential clinical consequences

Nature Reviews Clinical Oncology volume 14, pages 397–398 (2017)Cite this article

Subjects

The Cancer Genome Atlas Research Network recently published the most comprehensive, multi-omic molecular characterization of cervical cancers performed to date. The data reveal novel disease subtypes, and provide new insights into the aetiology and pathogenesis of cervical cancer. Importantly, the information obtained has potentially major clinical implications.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tewari, K. S. et al. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 370, 734–743 (2014).

    Article  CAS  Google Scholar 

  2. Thaker, P. H. et al. A phase I trial of paclitaxel, cisplatin and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Ann. Oncol. 28, 505–511 (2017).

    CAS  PubMed  Google Scholar 

  3. Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature 543, 378–384 (2017).

  4. Warren, C. J. et al. APOBEC3A functions as a restriction factor of human papillomavirus. J. Virol. 89, 688–702 (2015).

    Article  Google Scholar 

  5. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576–582 (2015).

  6. Verlaat, W. et al. Somatic mutation in PIK3CA is a late event in cervical carcinogenesis. J. Pathol. Clin. Res. 1, 207–211 (2015).

    Article  CAS  Google Scholar 

  7. Wang, F. et al. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am. J. Pathol. 179, 2580–2588 (2011).

    Article  CAS  Google Scholar 

  8. Bierkens, M. et al. Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosomes Cancer 52, 56–68 (2013).

    Article  CAS  Google Scholar 

  9. Tian, Q. et al. MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women. J. Natl Cancer Inst. 106, dju241 (2014).

    Article  Google Scholar 

  10. Stich, M. et al. 5-aza-2′-deoxycytidine (DAC) treatment downregulates the HPV E6 and E7 oncogene expression and blocks neoplastic growth of HPV-associated cancer cells. Oncotarget http://dx.doi.org/10.18632/oncotarget.10631 (2016).

  11. Kusanagi, Y. et al. Absence of HPV detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am. J. Pathol. 177, 2169–2175 (2010).

    Article  Google Scholar 

  12. Rodríguez-Carunchio, L. et al. HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. BJOG 122, 119–127 (2015).

    Article  Google Scholar 

Download references

Acknowledgements

C.J.L.M.M. is supported by the European Research Council (ERC advanced programme) via grant ERC-2012-AdG-322986-MASS-CARE.

Author information

Authors and Affiliations

  1. Chris J. L. M.Meijer and Renske D. M. Steenbergen are at the Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.,

    Chris J. L. M. Meijer & Renske D. M. Steenbergen

Authors
  1. Chris J. L. M. Meijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renske D. M. Steenbergen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chris J. L. M. Meijer.

Ethics declarations

Competing interests

C.J.L.M.M. and R.D.M.S. have minority stakes in Self-Screen, a spin-off company of VU University Medical Center. C.J.L.M.M. has received speakers bureau from GSK, Menarini, Merck, Qiagen, Roche, and Seegene; has occasionally served on the scientific advisory board of GSK, Merck, Qiagen, and Roche; and has occasionally been a consultant for Genticel and Qiagen. Until April 2016, he had shares in Diassay.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meijer, C., Steenbergen, R. Novel molecular subtypes of cervical cancer — potential clinical consequences. Nat Rev Clin Oncol 14, 397–398 (2017). https://doi.org/10.1038/nrclinonc.2017.52

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.52

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer